StockData
Abivax S.A. logo

Abivax S.A. (ABVX) stock

ABVXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as AAVXF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 1/30
$83.83+1.73 (+2.11%)

Close on Nov 18, 2026Market cap $6.58BP/E –Yield –

Abivax free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Abivax's free cash flow for the twelve months ending Jun 30, 2026 was -€197.27M. For fiscal 2025 it was -€161.27M. The highest annual figure on record is -€45.10M in fiscal 2021.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-€161.27M–
FY2024Dec 31, 2024-€154.71M–
FY2023Dec 31, 2023-€97.40M–
FY2022Dec 31, 2022-€54.22M–
FY2021Dec 31, 2021-€45.10M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-€52.10M–
Q1 FY2026Mar 31, 2026-€50.57M–
Q4 FY2025Dec 31, 2025-€23.32M–
Q3 FY2025Sep 30, 2025-€71.28M–
Q2 FY2025Jun 30, 2025-€33.36M–
Q1 FY2025Mar 31, 2025-€33.32M–
Q4 FY2024Dec 31, 2024-€33.61M–
Q3 FY2024Sep 30, 2024-€35.69M–
Q2 FY2024Jun 30, 2024-€50.65M–
Q1 FY2024Mar 31, 2024-€34.77M–

More Abivax figures

See a number that looks wrong?